Direct Plan · Growth Option · Sectoral / Thematic · Scheme code 152082
NAV₹22.6100as on 25 Sep 2026
Fund houseHDFC Mutual Fund
CategorySectoral / Thematic
Plan & optionDirect · Growth Option
History2.9 years
Returns (%)
1M
3M
6M
1Y
3Y
5Y
7Y
10Y
Launch
This scheme
3.08
12.96
23.07
28.85
—
—
—
—
32.45
Nifty 500 benchmark
0.87
4.31
2.15
5.20
12.49
11.41
—
—
15.49
Sectoral / Thematic category median
—
—
—
3.52
14.67
11.99
—
14.72
—
Over a year annualised (CAGR), under a year absolute. Computed from AMFI's published
NAV history for this scheme.
Risk
Volatility
Sharpe
Sortino
Beta
Alpha
Max fall
R²
This scheme
13.9%
1.87
2.74
0.71
22.38%
-14.9%
46.19
Nifty 500 benchmark
17.2%
0.35
0.47
—
—
-37.3%
—
Risk-free rate 6.5%. Beta, alpha and R² are regressed on the
34 months this scheme and its benchmark share.
Growth of ₹100 since launch
Drawdown from peak (%)
Every one-year period it has lived through
Windows
Worst
Median
Best
Periods that lost money
95
2.7%
22.6%
66.9%
0%
Every one-year holding period in this scheme's history, not just the last one — the
spread a real investor would have met depending only on when they started.
How it behaves against its benchmark
Up capture
Down capture
Correlation
Tracking error
Information ratio
Treynor
129%
34%
0.68
12.7%
1.61
38.41
Up capture is how much of the benchmark's gain this scheme kept in the months the
benchmark rose; down capture, how much of its fall it took. Below 100 on the down side and above it
on the up side is the combination every fund is trying for and few reach.
Measured over the 34 months this scheme and
Nifty 500 share.
HDFC Pharma and Healthcare Fund
Direct Plan · Growth Option
Allocation
By asset
Equity
98.42%
Cash & Equivalents
1.58%
By market cap
Large Cap
27.89%
Mid Cap
33.16%
Small Cap
32.45%
Unclassified
4.92%
Concentration
Number of stocks
39
Top 5 stocks
30.66%
Top 10 stocks
48.86%
Top 20 stocks
75.06%
Lines in the filing
41
Largest holding
9.54%
Largest sector
Pharmaceuticals & Biotechnology 72.12%
Effective stocks
25.6
Sectors held
3
Cash
1.58%
Effective stocks is what the concentration works out to: a fund holding
39 names but most of its money in a few
behaves like a fund of 26. Cash includes repo and TREPS, which
every fund parks money in overnight.
Sector split
Pharmaceuticals & Biotechnology
72.12%
Healthcare Services
24.15%
Healthcare Equipment & Supplies
2.15%
Cash & Equivalents
1.58%
HDFC Pharma and Healthcare Fund
Direct Plan · Growth Option · holdings
Top 30 holdings
#
Company
Sector
Shares held
Value ₹ cr
% of fund
1
Divis Laboratories Ltd.
Pharmaceuticals & Biotechnology
333,687
316
9.54%
2
Sun Pharmaceutical Industries Ltd.
Pharmaceuticals & Biotechnology
1,491,549
296
8.94%
3
Torrent Pharmaceuticals Ltd.
Pharmaceuticals & Biotechnology
266,486
135
4.08%
4
Max Healthcare Institute Limited
Healthcare Services
1,288,696
134
4.06%
5
Lupin Ltd.
Pharmaceuticals & Biotechnology
611,505
134
4.04%
6
Cipla Ltd.
Pharmaceuticals & Biotechnology
925,035
130
3.94%
7
Aster DM Quality Care Limited
Healthcare Services
1,681,027
127
3.84%
8
Neuland Laboratories Limited
Pharmaceuticals & Biotechnology
53,164
122
3.70%
9
Anthem Biosciences Limited
Pharmaceuticals & Biotechnology
1,291,629
115
3.48%
10
Acutaas Chemicals Limited
Pharmaceuticals & Biotechnology
339,010
107
3.24%
11
Ipca Laboratories Ltd.
Pharmaceuticals & Biotechnology
541,736
107
3.23%
12
Shilpa Medicare Ltd
Pharmaceuticals & Biotechnology
1,080,751
103
3.10%
13
Alkem Laboratories Ltd.
Pharmaceuticals & Biotechnology
189,824
101
3.06%
14
Global Health Limited
Healthcare Services
637,841
94
2.85%
15
Rubicon Research Limited
Pharmaceuticals & Biotechnology
512,696
93
2.82%
16
Fortis Healthcare Limited
Healthcare Services
866,882
79
2.37%
17
Glenmark Pharmaceuticals Ltd.
Pharmaceuticals & Biotechnology
312,887
78
2.34%
18
Krishna Institute Of Medical Sciences Limited
Healthcare Services
984,676
74
2.25%
19
Vijaya Diagnostic Centre Limited
Healthcare Services
488,093
74
2.24%
20
Jupiter Life Line Hospitals Limited
Healthcare Services
2,175,025
64
1.94%
21
Zydus Lifesciences Limited
Pharmaceuticals & Biotechnology
548,897
64
1.93%
22
Dr Reddys Laboratories Ltd.
Pharmaceuticals & Biotechnology
544,958
63
1.90%
23
Metropolis Healthcare Ltd.
Healthcare Services
1,081,488
63
1.90%
24
TREPS - Tri-party Repo
Unclassified
—
61
1.83%
25
Molbio Diagnostics Limited
Healthcare Equipment & Supplies
538,006
58
1.77%
26
Biocon Ltd.
Pharmaceuticals & Biotechnology
1,390,421
57
1.73%
27
Wockhardt Ltd.
Pharmaceuticals & Biotechnology
283,279
53
1.61%
28
Sai Life Sciences Limited
Pharmaceuticals & Biotechnology
361,951
53
1.60%
29
Apollo Hospitals Enterprise Ltd.
Healthcare Services
51,700
46
1.39%
30
Thyrocare Technologies Ltd.
Healthcare Services
719,111
43
1.31%
HDFC Pharma and Healthcare Fund
Direct Plan · Growth Option · where the money sits
What the manager did last month
Between the filings of 31 Jul 2026 and 31 Aug 2026.
A position grows because the manager bought or because the price rose; only the share count separates them.
Bought
Sold
New positions
Sold out of
Price move of holdings
₹136 cr
₹7 cr
2
0
+5.00%
Stock
Shares traded
Shares
Price
Value ₹ cr
New position
Molbio Diagnostics Limited
538,006
entered
—
58.4
SYMBIOTEC PHARMALAB LIMITED
404,865
entered
—
40.0
Added to
Torrent Pharmaceuticals Ltd.
135,486
+103.4%
-1.1%
68.6
Rubicon Research Limited
195,476
+61.6%
+22.0%
35.6
Sun Pharmaceutical Industries Ltd.
65,500
+4.6%
-0.3%
13.0
Lupin Ltd.
43,231
+7.6%
-9.4%
9.5
Dr Reddys Laboratories Ltd.
53,000
+10.8%
+0.6%
6.1
Neuland Laboratories Limited
660
+1.3%
+20.8%
1.5
Alkem Laboratories Ltd.
2,330
+1.2%
-7.3%
1.2
Novartis India Ltd.
3,597
+3.7%
+1.1%
0.6
Trimmed
Glenmark Pharmaceuticals Ltd.
28,000
-8.2%
+11.0%
6.9
Not equity
Previous filing
This filing
Change
Cash, repo and TREPS
₹0 cr
₹0 cr
+₹0 cr
The list above is stocks and fund units. Treasury bills, repo and money-market
lines roll over every month by design — they are not decisions, so they are totalled here rather
than listed as activity.
Not investment advice. InvestVerdict is not a SEBI-registered Investment Adviser or Research Analyst. Every figure is computed from AMFI's published NAV history and the
portfolio the AMC filed with AMFI; none of it is a recommendation to buy, hold or sell. Past
returns do not predict future ones. Generated 27 Sep 2026.
